Synonym
JNJ-26489112; JNJ26489112; JNJ 26489112
IUPAC/Chemical Name
Sulfamide, [[(2S)-6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-
InChi Key
KXSAIQPPGSSNKX-ZETCQYMHSA-N
InChi Code
InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
SMILES Code
O=S(NC[C@@H]1OC2=CC=C(Cl)C=C2OC1)(N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
278.71
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White
HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N,
Reitz AB, Maryanoff BE. Novel, broad-spectrum anticonvulsants containing a
sulfamide group: pharmacological properties of
(S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
(JNJ-26489112). J Med Chem. 2013 Nov 27;56(22):9019-30. doi: 10.1021/jm400894u.
PubMed PMID: 24205976; PubMed Central PMCID: PMC4004761.
2: Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, Xi L, Nye
JS, Kasteleijn-Nolst Trenité D. Evaluation of JNJ-26489112 in patients with
photosensitive epilepsy: a placebo-controlled, exploratory study. Epilepsy Res.
2014 May;108(4):709-16. doi: 10.1016/j.eplepsyres.2014.01.018. PubMed PMID:
24560845.
3: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, Di
Prospero NA, Pandina G, Singh JB, Ford L, Moyer JA, Nork TM, Ver Hoeve JN,
Aguirre GD. Implications of retinal effects observed in chronic toxicity studies
on the clinical development of a CNS-active drug candidate. Regul Toxicol
Pharmacol. 2014 Jul;69(2):187-200. doi: 10.1016/j.yrtph.2014.03.005. PubMed PMID:
24680767.
4: Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A
review of potential anti-seizure drugs in clinical development. Pharmacol Res.
2016 Feb;104:38-48. doi: 10.1016/j.phrs.2015.12.011. Review. PubMed PMID:
26689774.
5: Mariën D, Bailey GP, Eichenbaum G, De Jonghe S. Timing is everything for sperm
assessment in fertility studies. Reprod Toxicol. 2016 Sep;64:141-50. doi:
10.1016/j.reprotox.2016.05.001. PubMed PMID: 27181369.
